New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

AudioMedica News
AudioMedica News
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Loading
/
Terry Gernsheimer
Terry Gernsheimer

TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.

[audio:https://www.audiomedica.com/podcasting/oncology/071208_terry_gernsheimer.mp3]
1 comment
  • Would the AMG 531 be something you would recommend to a young lady in childbearing ages wanting to persue fertility in hopes to become pregnant? Is this a better option than having the spleen removed?

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality